Banco Santander S.A. Has $2.05 Million Stake in Sanofi (NASDAQ:SNY)

Banco Santander S.A. increased its holdings in Sanofi (NASDAQ:SNY) by 11.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,494 shares of the company’s stock after buying an additional 4,428 shares during the period. Banco Santander S.A.’s holdings in Sanofi were worth $2,049,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SNY. Synergy Asset Management LLC acquired a new position in Sanofi during the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. raised its position in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Sunbelt Securities Inc. raised its position in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares in the last quarter. Sierra Ocean LLC acquired a new position in Sanofi during the fourth quarter valued at approximately $44,000. Finally, Versant Capital Management Inc acquired a new position in Sanofi during the fourth quarter valued at approximately $54,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have commented on SNY shares. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Stock Performance

NASDAQ SNY opened at $59.25 on Monday. The firm’s fifty day moving average price is $52.65 and its two-hundred day moving average price is $52.73. The stock has a market cap of $150.37 billion, a PE ratio of 23.80, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $59.72. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.